– SIMPLIFY YOUR AST WORKFLOW
dRAST™ is a rapid AST platform that identifies optimal antimicrobial after a positive blood culture, while other conventional systems take 2-3 days
Fast AST in 4 hours from positive blood culture
Up to 19 different antibiotics in several concentrations in one run
Use the right antibiotic sooner and reduce amount of broad spectrum
Let dRASTTM handle your AST workflow while you are doing something else
EXPERIENCE THE POWER OF dRAST’S RANDOM ACCESS CAPABILITY AND IMPROVE YOUR LABORATORY TURN-AROUND TIME
Rapid AST with
MIC & SIR direct from PBC
Full Expert System on board
with dynamic algorithm
Easy to use interface
with low hands-on time
Continuous loading for optimal handling of urgent care patients
Incorporationg international guidelines & recommendations: EUCAST, CLSI & CA-SFM
LIS BI-directional with easy Bacteria
An overall combined CA for both GNs and GPs of 96.3%. The presented time to report data obtained by QMAC-dRASTTM in this study being of 3-8 hours for blood-culture specimens examined strongly support a further possible improvement in the workflow for handling blood stream infections.
Jens Jørgen Christensen, clinical professor
The regional department of clinical microbiology, Zeeland University Hospital
Reporting based on MALDI-TOF MS results on susceptible/resistant pathogens, optimal targeted treatment was found respectively in 79%/63%, unnecessary broad-spectrum treatment in 16%/5%, suboptimal treatment in 4%/1%, and appropriate antibiotic treatment 100%/68%. Adding QMAC-dRASTTM results to the decision making raised the percentage of optimal antibiotic treatments to 98.2%
Chemother. 2019 Aug;74(8):2255–60.
Patended 96 Wells Plate with Dried Antibiotics
Gram Positive / Gram Negative panels for positive blood culture
Reporting Susceptibility by Prorietary Algoritm and Database
Automated image processing for growth measurement.S I R(Susceptible, Intermediate and Resistant) determination based on database and expert rules in collaboration with EUCAST.
Less Loading more Efficiency
By eliminating requirement for sub-cultures, dRAST™ improves your lab efficiency by reducing TAT for Antibiotic Susceptibility testing
dRAST™ system does not require turbidity measurements
dRAST™ is the solution to help you care for Sepsis patients
Frequently Asked Questions
on dRASTTM GN panel, we feature 4 drug mixes:
-Cefotaxime / Clavulanic acid
-Ceftazidime / Clavulanic acid
Based on CLSI decision matrix, dRASTTM will analyze the difference of MIC within these 4 drug mixes.
dRASTTM will therefore produce an ESBL result : Negative or Positive based on MIC differences
With 8 wells on Imipenem and 8 wells on Meropenem, we have a very clear MIC result which clearly indicates if the bacteria is resistant or not to carbapenem drugs. This also applies to Pseudomonas aeruginosa and Acinetobacter baumannii
dRASTTM does not feature an AmpC flag per se but with the 3 cephalosporin drugs present on GN panel (Cefepime, Cefotaxime, Ceftazidime), dRASTTM provides a clear susceptibility information regarding any resistance towards cephalosporin drugs.
For Staphylococcus aureus, Staphylococcus lugdunensis & Staphylococcus saprophyticus, we feature Oxacillin and Cefoxitin Screen which clearly indicates the difference between MRSA & MSSA.For other Staphylococcus species, resistance is determined on Oxacillin MIC results. Cefoxitin Screen is less susceptible for these species.
Yes. If the strain is resistant to Erythromycin, in this case, dRASTTM considers the iCLI well on GP panel (mix of Erythromycin/Clindamycin). If any growth on iCLI well, iCLI appears positive and resistance to Clindamycin is detected
With 7 wells on Vancomycin, MIC result is produced on Vancomycin providing clear indication of VRE.
With 7 wells on Teicoplanin and 7 wells on Vancomycin, MIC result is produced on dRASTTM providing clear indication of GISA presence.
Other interesting content
Looking for something else? You might be interested in this as well.
Please, reach out if you have questions, comments or requests.